Copyright
©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 28, 2011; 17(44): 4858-4866
Published online Nov 28, 2011. doi: 10.3748/wjg.v17.i44.4858
Published online Nov 28, 2011. doi: 10.3748/wjg.v17.i44.4858
Figure 7 Effects of erlotinib on RIE-1 cells.
A: Cells were incubated in RPMI 1640-5% FBS with or without EGF (10 ng/mL) and the indicated concentrations of erlotinib for 24 h. Cells were also pretreated with indicated concentration of erlotinib for 24 h and then stimulated with EGF (10 ng/mL) for 5 min. Cell lysates were analyzed by immunoblotting with indicated antibodies; B and C: Cell proliferation was assayed in the presence or absence of EGF (10 ng/mL) or erlotinib (10 μmol/L) as described in the Materials and Methods. EGF: Epidermal growth factor.
- Citation: Pagán B, Isidro AA, Cruz ML, Ren Y, Coppola D, Wu J, Appleyard CB. Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model. World J Gastroenterol 2011; 17(44): 4858-4866
- URL: https://www.wjgnet.com/1007-9327/full/v17/i44/4858.htm
- DOI: https://dx.doi.org/10.3748/wjg.v17.i44.4858